Darzalex (daratumumab) - J&J
Rituxan (rituximab) - Roche
bortezomib - Generic mfg.
sirolimus - Generic mfg.
Autoimmune Cytopenia and Pure Red Cell Aplasia after HSCT (ICBMT 2026) - Oct 8, 2026 - Abstract #ES02-1; Pres time: Sep 18, 2026; 10:10 AM - 10:40 AM; Location: Room D(2F); "For AIC, corticosteroids, intravenous immunoglobulin, rituximab, sirolimus, thrombopoietin receptor agonists, bortezomib, and emerging targeted agents may be considered. For PRCA, management includes transfusion support, iron monitoring, erythropoietin, plasma exchange or immunoadsorption, immunosuppression tapering, rituximab, bortezomib, and increasingly daratumumab." 
Autoimmune Hemolytic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immune Thrombocytopenic Purpura • Immunology • Infectious Disease • Neutropenia • Primary Immunodeficiency • Thrombocytopenia • Thrombocytopenic Purpura • Transplantation Associated Thrombotic Microangiopathy
https://icbmt.or.kr/2026/data/ICBMT2026_AbstractBook_Lite.pdf
 
Kyung Taek Hong
 
Oct 8, 2026
 
Prev Next